CY1105982T1 - Συνδετες υποδοχεων γλυκοκορτικοειδων για την θepαπεια των μεταβολικων διαταραχων - Google Patents

Συνδετες υποδοχεων γλυκοκορτικοειδων για την θepαπεια των μεταβολικων διαταραχων

Info

Publication number
CY1105982T1
CY1105982T1 CY20071100150T CY071100150T CY1105982T1 CY 1105982 T1 CY1105982 T1 CY 1105982T1 CY 20071100150 T CY20071100150 T CY 20071100150T CY 071100150 T CY071100150 T CY 071100150T CY 1105982 T1 CY1105982 T1 CY 1105982T1
Authority
CY
Cyprus
Prior art keywords
glucocortico
treatment
metabolic disorders
receptor binders
compounds
Prior art date
Application number
CY20071100150T
Other languages
English (en)
Inventor
Thomas W. Von Geldern
James T. Link
Noah Tu
Philip R. Kym
Chunqiu Lai
Steven J. Richards
Peer B. Jacobson
Richard D. Bishop
Bradley D. Gates
Original Assignee
Karo Bio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/460,491 external-priority patent/US7141559B2/en
Application filed by Karo Bio Ab filed Critical Karo Bio Ab
Publication of CY1105982T1 publication Critical patent/CY1105982T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Αυτή η ευρεσιτεχνία σχετίζεται με τα καινοτόμα προϊόντα τα οποία είναι οι ηπατοεκλεκτικοί ανταγωνιστές των υποδοχέων γλυκοκορτικοειδών, με μεθόδους παρασκευής τέτοιων ενώσεων και με μεθόδους για την χρησιμοποίηση τέτοιων ενώσεων στην ρύθμιση του μεταβολισμού, ειδικότερα στην μείωση των επιπέδων του ορού της γλυκόζης, των επιπέδων της ινσουλίνης ή των επιπέδων των λιπιδίων και/ή της μείωσης του βάρους σώματος.
CY20071100150T 2002-06-19 2007-02-02 Συνδετες υποδοχεων γλυκοκορτικοειδων για την θepαπεια των μεταβολικων διαταραχων CY1105982T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17475002A 2002-06-19 2002-06-19
US10/460,491 US7141559B2 (en) 2002-06-19 2003-06-12 Glucocorticoid receptor ligands for the treatment of metabolic disorders
PCT/US2003/019157 WO2004000869A1 (en) 2002-06-19 2003-06-17 Glucocorticoid receptor ligands for the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
CY1105982T1 true CY1105982T1 (el) 2011-04-06

Family

ID=30002639

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100150T CY1105982T1 (el) 2002-06-19 2007-02-02 Συνδετες υποδοχεων γλυκοκορτικοειδων για την θepαπεια των μεταβολικων διαταραχων

Country Status (16)

Country Link
EP (1) EP1551860B1 (el)
JP (1) JP4611019B2 (el)
KR (1) KR101100826B1 (el)
CN (1) CN100348609C (el)
AR (1) AR040278A1 (el)
AT (1) ATE346082T1 (el)
AU (1) AU2003243622B9 (el)
CA (1) CA2488535C (el)
CY (1) CY1105982T1 (el)
DE (1) DE60309909T2 (el)
DK (1) DK1551860T3 (el)
ES (1) ES2278195T3 (el)
PT (1) PT1551860E (el)
TW (1) TWI285646B (el)
UY (1) UY27862A1 (el)
WO (1) WO2004000869A1 (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7569689B2 (en) 2004-01-16 2009-08-04 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7326728B2 (en) 2004-01-16 2008-02-05 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof
US7253283B2 (en) 2004-01-16 2007-08-07 Bristol-Myers Squibb Company Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7605264B2 (en) 2004-01-16 2009-10-20 Bristol-Myers Squibb Company Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7625921B2 (en) 2004-01-16 2009-12-01 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7642273B2 (en) 2005-01-13 2010-01-05 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7411071B2 (en) 2005-01-13 2008-08-12 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7361654B2 (en) 2005-01-13 2008-04-22 Bristol-Myers Squibb Co. Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
GB0514302D0 (en) * 2005-07-12 2005-08-17 Karobio Ab Improved crystalline material
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP2013510834A (ja) 2009-11-16 2013-03-28 メリテク ［１，５］‐ジアゾシン誘導体
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
PE20140859A1 (es) 2011-02-25 2014-07-25 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos
CN103957919B (zh) * 2011-09-19 2018-10-16 瑞士苏黎世联邦理工学院 RORγ调节剂
BR112015002080A2 (pt) 2012-08-02 2017-07-04 Merck Sharp & Dohme composto, composição farmacêutica, uso de um composto, e, método de tratamento ou de prevenção de um transtorno, de uma condição ou de uma doença
EP2958562A4 (en) 2013-02-22 2016-08-10 Merck Sharp & Dohme BICYCLIC ANTIDIABETIC COMPOUNDS
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
EP2781217A1 (en) * 2013-03-18 2014-09-24 ETH Zurich ROR gamma modulators
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN105693808B (zh) * 2015-11-05 2018-03-16 华润紫竹药业有限公司 一种醋酸乌立妥原料药杂质及其制备方法和作为标准品的用途
FR3055627A1 (fr) * 2016-09-08 2018-03-09 Laboratoire Hra-Pharma Methode de preparation du compose cdb-3877
FR3055626B1 (fr) * 2016-09-08 2018-10-12 Hra Pharma Lab Procede de synthese d'un compose steroide comprenant un substituant n-methylaniline en position 11
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN114230627B (zh) * 2021-12-31 2023-09-15 湖南新合新生物医药有限公司 一种倍他米松环氧水解物中间体的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3930696A1 (de) * 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
DE4000397A1 (de) * 1990-01-09 1991-07-11 Hoechst Ag Lipidselektive antioxidantien sowie deren herstellung und verwendung
IL100240A (en) * 1990-12-06 1995-10-31 Hoechst Ag History of bile acids, the process for their preparation and pharmaceutical preparations containing them
GB9907048D0 (en) * 1999-03-27 1999-05-19 Karobio Ab Novel glucocorticoid receptor ligands for the treatment of meta bolic disorders

Also Published As

Publication number Publication date
WO2004000869A1 (en) 2003-12-31
TWI285646B (en) 2007-08-21
KR101100826B1 (ko) 2012-01-02
JP4611019B2 (ja) 2011-01-12
JP2005533807A (ja) 2005-11-10
AR040278A1 (es) 2005-03-23
AU2003243622A2 (en) 2004-01-06
DE60309909T2 (de) 2007-06-21
CN100348609C (zh) 2007-11-14
KR20050016588A (ko) 2005-02-21
UY27862A1 (es) 2004-04-30
EP1551860B1 (en) 2006-11-22
ATE346082T1 (de) 2006-12-15
AU2003243622A1 (en) 2004-01-06
TW200410983A (en) 2004-07-01
ES2278195T3 (es) 2007-08-01
CA2488535C (en) 2012-02-07
DK1551860T3 (da) 2007-04-02
CN1662549A (zh) 2005-08-31
EP1551860A1 (en) 2005-07-13
DE60309909D1 (de) 2007-01-04
AU2003243622B9 (en) 2009-07-16
PT1551860E (pt) 2007-02-28
CA2488535A1 (en) 2003-12-31
AU2003243622B2 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
CY1105982T1 (el) Συνδετες υποδοχεων γλυκοκορτικοειδων για την θepαπεια των μεταβολικων διαταραχων
ATE490984T1 (de) Methode zur produktion und evaluierung der zytotoxizität von kir2dl nk-rezeptor antikörpern
PT1054887E (pt) Derivados biciclicos de piridina e pirimidina como antagonistas de receptores no neuropeptido y
CY1111757T1 (el) Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α
CY1115188T1 (el) Πολυκυκλικες ετεροαρυλ-υποκατεστημενες τριαζολες χρησιμες ως αναστολεις του axl
SG162807A1 (en) Azaindazole compounds and methods of use
CY1108752T1 (el) Παραγωγα πουρινης δρωντα ως αγωνιστες του α2α-υποδοχεα
SI1633726T1 (sl) Derivativi pirimidina, uporabni pri zdravljenju bolezni, posredovanih s crth 2
CY1108754T1 (el) Νεα παραγωγα θειοφαινογλυκοσιδης, μεθοδος για την παρασκευη τους, φαρμακα περιεχοντα αυτες τις ενωσεις και η χρηση τους
CA2412161A1 (en) Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones
MA29088B1 (fr) Composes d'indazole-carboxamide.
CY1107426T1 (el) Νεα παραγωγα φθοριογλυκοσιδιων απο πυραζολες, φαρμακευτικα προϊοντα που περιεχουν τις εν λογω ενωσεις και η χρηση αυτων
TW200612989A (en) Process for concentration of antibodies and therapeutic products thereof
CY1106003T1 (el) Παραγωγα του ν-βενζοϋλοουρεϊδο-κινναμωμικου οξεος, μεθοδος για την παρασκευη τους και η χρηση τους
JO3319B1 (ar) مركبات 3- (ايميدازول) - بيرازولو (3,4 - b ) بيريدين
CY1118203T1 (el) Κατιονika παραγωγα βακτηριοχλωροφυλλης και χρησεις αυτων
ATE546439T1 (de) Heterocyclische modulatoren der glucocorticoidrezeptor-, ap-1- und/oder nf-kb- aktivität und deren verwendung
ATE499350T1 (de) Modulatoren der glucocorticoidrezeptor-, ap-1- und/oder nf-kb-aktivität und deren verwendung
MXPA05005171A (es) Compuestos bi-aromaticos activadores de los receptores de tipo ppar-gama y su uso en composiciones cosmeticas o farmaceuticas.
CY1111256T1 (el) Παραγωγα αζαδικυκλοοκταν-3-ονης και χρηση τους
CY1112038T1 (el) Αναστολεις της κινασης τυροσινης
WO2005082457A3 (fr) Utilisation de derives d’indolizine 1,2,3 substitues pour le traitement de maladies liees à une angiogenese pathologique choroïdienne.
WO2000078776A3 (en) Thiophene a2a receptor agonists
MXPA05002418A (es) Derivados de 1,4-pirazina sustituidos.
NO20040811L (no) Diarylcykloalkylderivater, fremgangsmate for deres fremstilling og deres anvendelse som PPAR-aktivatorer.